{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Participants will be enrolled on the Phase I study portion in blocks of 3 to varying doses of Revlimid® (lenalidomide) and Vidaza® (azacitidine) (Table 1). To determine the MTD, a standard \"3+3\" design will be used. DLT will be assessed during the first cycle of therapy within each treatment group. No Maximum dose was reach but the go-forward dose agreed upon by the investigators is reported here.","groups":[{"description":"azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.\n\nlenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.","id":"OG000","title":"Lenalidomide and Azacitidine"}],"paramType":"NUMBER","populationDescription":"Participants in Phase I","reportingStatus":"POSTED","timeFrame":"After 1 courses (1 months)","title":"PHASE I: Maximum Tolerated Dose of Azacitidine","type":"PRIMARY","unitOfMeasure":"mg/m2 subcutaneously for 5 days"}